Trials / Unknown
UnknownNCT04087915
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD)
A Perspective, Cohort Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab is Used in Combination With Statin Therapy In Patients With High Risk Cardiovascular Disease
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Beijing Anzhen Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective was to evaluate the effect of treatment with evolocumab on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in patients with high risk coronary artery disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Evolocumab | Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference |
Timeline
- Start date
- 2019-09-11
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2019-09-12
- Last updated
- 2020-12-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04087915. Inclusion in this directory is not an endorsement.